Published in Sb Lek on February 01, 1980
Third consensus on medical treatment of metastatic breast cancer. Ann Oncol (2009) 1.96
Second consensus on medical treatment of metastatic breast cancer. Ann Oncol (2006) 1.37
Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer (2006) 1.07
Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up. Dis Esophagus (2009) 1.05
Dietary habits and lung cancer risk among non-smoking women. Eur J Cancer Prev (2004) 0.98
Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann Oncol (2003) 0.89
Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Ann Oncol (2009) 0.87
Outcomes of patients with oesophageal cancer treated with preoperative chemoradiotherapy, followed by tumor resection: influence of nutritional factors. J BUON (2012) 0.85
Carbonyl and oxidative stress in patients with breast cancer--is there a relation to the stage of the disease? Neoplasma (2007) 0.84
Large expansion of morphologically heterogeneous mammary epithelial cells, including the luminal phenotype, from human breast tumours. Breast Cancer Res Treat (2002) 0.83
Lung cancer risk among nonsmoking women in relation to diet and physical activity. Neoplasma (2004) 0.83
[Meningeal carcinomatosis as the first manifestation of gastric adenocarcinoma]. Cas Lek Cesk (2001) 0.83
Diet and the risk of lung cancer among women. A hospital-based case-control study. Neoplasma (2001) 0.80
Agents affecting porphyrin formation and secretion: implications for porphyria cutanea treatment. Semin Hematol (1989) 0.79
Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients. Neoplasma (2001) 0.79
Mammaglobin A, a novel marker of minimal residual disease in early stages breast cancer. Neoplasma (2004) 0.78
Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations. Br J Cancer (2003) 0.78
Comparative analysis of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in colorectal cancer and surrounding normal tissue. Neoplasma (2005) 0.78
Predictive factors for the presence of tumor cells in bone marrow and peripheral blood in breast cancer patients. Neoplasma (2015) 0.77
[The effect of a single administration of captopril on portal flow as measured by the Doppler method]. Cas Lek Cesk (1988) 0.77
Mutations of the BRCA1 gene in hereditary breast and ovarian cancer in the Czech Republic. Med Princ Pract (2003) 0.77
Trefoil factor family (TFF) proteins as potential serum biomarkers in patients with metastatic colorectal cancer. Neoplasma (2015) 0.77
Influence of chemotherapy to hormonal levels in postmenopausal breast cancer patients. Neoplasma (2008) 0.77
Treatment of locally advanced pancreatic cancer by percutaneous and intraoperative irreversible electroporation: general hospital cancer center experience. Neoplasma (2016) 0.76
Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. Lung Cancer (1998) 0.76
[A comprehensive diagnostic approach to tumor metastases in the skeleton. VI. The bone marrow in the metastatic process in malignant neoplasms]. Cas Lek Cesk (1987) 0.75
[HLA system in symptomatic hepatic porphyria (author's transl)]. Cas Lek Cesk (1981) 0.75
[Immunologic profile of malignant melanoma as a basis for further treatment]. Cesk Dermatol (1980) 0.75
[Dysplastic nevus (introduction to the problem)]. Cesk Patol (1987) 0.75
Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group. Ann Oncol (1996) 0.75
[Cervical carcinoma during pregnancy]. Ceska Gynekol (2000) 0.75
PET/CT significance for planning radiotherapy of head and neck cancer. Neoplasma (2012) 0.75
[Use of PET/CT examination in head and neck cancer radiotherapy planning]. Klin Onkol (2009) 0.75
[Changes in leptin, leptin receptor and fatty acids levels during chemoradiotherapy for oesophageal cancer]. Cas Lek Cesk (2005) 0.75
[Comprehensive diagnostic approaches to tumor metastases in the skeleton. IV. Cytomorphologic and biochemical diagnosis of bone metastases of stage II carcinoma of the breast]. Cas Lek Cesk (1987) 0.75
[Electron microscopy findings in lichen planus]. Cesk Patol (1988) 0.75
[Coelomic cysts simulating goiter and hydrocele]. Cas Lek Cesk (1982) 0.75
Postoperative radiochemotherapy with weekly cisplatin in patients with head and neck cancer single-institution outcome analysis. Neoplasma (2012) 0.75
[Diagnosis and therapy of malignant tumors of the nasopharynx]. Sb Lek (1984) 0.75
The growth of lymphocyte colonies from peripheral blood of patients with malignant melanoma. Neoplasma (1984) 0.75
[Essential phospholipids in the treatment of liver cirrhosis]. Cas Lek Cesk (1983) 0.75
HER-2 tissue expression correlated with serum levels in breast cancer patients. Folia Biol (Praha) (2007) 0.75
[Hemocoagulation status in reinfusion of ascitic fluid in patients with liver cirrhosis]. Cas Lek Cesk (1985) 0.75
[Lamellae annulatae and cisternae radiatae in human tumor cells]. Cesk Patol (1980) 0.75
[Histological, electron-optical and histochemical findings in mycosis fungoides]. Cesk Patol (1978) 0.75
[Tamoxifen or tamoxifen in combination with chemotherapy in adjuvant therapy of breast carcinoma. Results of a multicenter randomized study]. Sb Lek (2001) 0.75
[Our 2-year experience with the reinfusion of concentrated ascitic fluid in liver cirrhosis with emphasis on the hemodynamic effects of the renin-angiotensin-aldosterone system]. Cas Lek Cesk (1984) 0.75
[Recombinant erythropoietin (r-HuEPO) in the treatment of anemia in multiple myeloma]. Cas Lek Cesk (1996) 0.75
[Dysplastic nevi--clinical and histological picture]. Sb Lek (1988) 0.75
[Present trends and methodological basis for the cognitive process in pathology]. Cas Lek Cesk (1983) 0.75
[Immunoscore and Its Predictive Value for Colorectal Cancer]. Klin Onkol (2015) 0.75
[Treatment of febrile neutropenia in patients with solid tumors]. Cas Lek Cesk (1998) 0.75
[Symptomatic liver porphyria with a familial incidence]. Cas Lek Cesk (1985) 0.75
Molecular detection of disseminated breast cancer cells in the bone marrow of early breast cancer patients using quantitative RT PCR for CEA. Neoplasma (2008) 0.75
[Comments on the Pathogenesis and therapy of ascites in cirrhosis of the liver]. Cas Lek Cesk (1982) 0.75
[Controlling the binding of porphyrins to ligands using antimalarial agents]. Cas Lek Cesk (1984) 0.75
[Prognostic factors in non-Hodgkin's malignant lymphoma]. Sb Lek (1991) 0.75
[Changes of hepatocytes during starvation]. Cesk Patol (1973) 0.75
Predicting axillary sentinel node status in patients with primary breast cancer. Neoplasma (2013) 0.75
[Effect of pyrimethamine on clinical and biochemical manifestations of symptomatic liver porphyria]. Cas Lek Cesk (1983) 0.75
[Treatment of colorectal liver metastases: a current view]. Klin Onkol (2010) 0.75
[Personal experience with the reinfusion of concentrated ascitic fluid in liver cirrhosis]. Cas Lek Cesk (1983) 0.75
[Dibromodulcitol in combination with actinotherapy of spinocellular carcinoma]. Sb Lek (1984) 0.75
[X-ray picture of enchondroma]. Fysiatr Revmatol Vestn (1972) 0.75
[Neutron capture therapy in the treatment of glioblastoma multiforme. Initial experience in the Czech Republic]. Cas Lek Cesk (2004) 0.75
[A large metastasis of colorectal carcinoma--case report]. Rozhl Chir (1998) 0.75
[Complex diagnosis and therapy of malignant melanoma with a special emphasis on adjuvant treatment of clinical stage I]. Cesk Dermatol (1980) 0.75
[Analgesic effect of videothoracoscopic splanchnicectomy]. Sb Lek (2002) 0.75
[Guideline for gynecological malignant tumors I. Standard--a complex therapy of ovarian epithelial malignant tumors]. Ceska Gynekol (2006) 0.75
Parasitism and pathogenic activity of Cytospora cincta Sacc. on Prunus armeniaca L. and on Prunus persica L. Batsch. Biologia (Bratisl) (1970) 0.75
[Binding of porphyrins to intracellular proteins]. Cas Lek Cesk (1984) 0.75
[Chemotherapy and biological treatment in the complex management of large intestinal and rectal carcinomas. When, why, how?]. Rozhl Chir (2009) 0.75
[Malignant mucosal melanoma of the head and neck]. Sb Lek (2000) 0.75
[2 years' experience with the treatment of symptomatic liver porphyria with pyrimethamine]. Cas Lek Cesk (1985) 0.75
[Non-Hodgkin's malignant lymphoma with a low level of malignancy]. Sb Lek (1987) 0.75
[Prophylactic adnexectomy]. Ceska Gynekol (2004) 0.75
[Alpha-2-macroglobulin associated with pregnancy and monitored with quantitative immunoelectrophoresis during cancer involvement]. Cas Lek Cesk (1982) 0.75
[The Shy-Drager syndrome]. Cesk Patol (1987) 0.75
[A comprehensive diagnostic approach to tumor metastasis in the skeleton. VII. Perspectives in the development of additional diagnostic methods for the detection of bone marrow and bone metastases of malignant neoplasms]. Cas Lek Cesk (1987) 0.75
[Lever's adenoacanthoma]. Cesk Patol (1972) 0.75
[Conservative surgical treatment of breast carcinoma in women from the viewpoint of the oncologist-radiotherapist]. Rozhl Chir (1994) 0.75
[Malignant atrophic papulosis (Degos' syndrome)]. Sb Lek (1990) 0.75
[Clinical utility of bone markers in the evaluation and follow-up in patients with neoplastic bone diseases]. Cas Lek Cesk (2008) 0.75
[Epithelial tumor-like changes, precancerous conditions and skin neoplasms (standardization study)]. Cesk Patol (1976) 0.75
[Analysis of the 1st results of single-photon emission tomography in the detection of focal lesions in Hodgkin's disease and in liver tumors]. Cas Lek Cesk (1986) 0.75
[Prognostic factors in non-Hodgkin's malignant lymphoma]. Sb Lek (1991) 0.75
Population-based study of BRCA1/2 mutations: family history based criteria identify minority of mutation carriers. Neoplasma (2010) 0.75
Cellular and humoral immunodeficiency in breast cancer patients resistant to hormone therapy. Neoplasma (2014) 0.75
[Minimal residual disease in breast carcinoma]. Cas Lek Cesk (2002) 0.75
[Recombinant human erythropoietin in the treatment of anemia associated with lymphoproliferative diseases--chronic lymphadenosis and multiple myeloma]. Vnitr Lek (1996) 0.75